Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- WORLD BUSINESS NEWS IN BRIEF
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -1-
March 12, 2001
- BUSINESS NEWS IN BRIEF -1-
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -2-
March 12, 2001
- Elsevier Science Acquires MIX
March 12, 2001
- Hitachi Spins Off Instruments, Semiconductor Manufacturing Equipment Businesses
March 12, 2001
- Maruishi: Sevofrane Pushes Sales to \32 Bil., Up 6.4%
March 12, 2001
- Mitsubishi Ties Up with TeraRecon in 3D Graphics Business
March 12, 2001
- Approval of 8 New Drugs Including Radicut, Fiblast Spray Granted
March 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 12, 2001
- More Strict with Hospitals in Illegal Cases: New Medical Service Law
March 12, 2001
- OTC NEWS IN BRIEF
March 12, 2001
- Nicorette Reexamined, 2 New Orphan Drugs Designated
March 12, 2001
- Sankyo Aims at \1 Trillion Sales in FY2010: President Takato
March 12, 2001
- Q&A Booklet on New PMS for 6 Months after Launching Issued
March 12, 2001
- MTP Ties Up with Sumitomo, MedGene Regarding HGF
March 12, 2001
- REGULATORY NEWS IN BRIEF
March 12, 2001
- Hokuriku: Hokunalin Tape, Ganaton Boost Sales, Operating Profits
March 12, 2001
- Taisho Signs Anti-Asthma Drug License Agreement with EpiGenesis
March 12, 2001
- JMARI to Conduct Survey to Propose New Medical Fee Payment Method
March 12, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…